Financial toxicity in patients with glioblastoma
- PMID: 39412733
- DOI: 10.1007/s11060-024-04835-8
Financial toxicity in patients with glioblastoma
Abstract
Purpose: There has been mounting interest in understanding the impact of financial toxicity (FT) in various cancer types; however, it remains poorly understood and understudied within neuro-oncology-especially as it relates to neurosurgical components of patient care.
Methods: Retrospective, single-center study of patients who underwent craniotomy for resection of glioblastoma from 2020 to 2022. OIBEE™ (Austin, Texas) software was queried to identify the subset of these patients who had a bad debt charged to their account. These patients were deemed to qualify as experiencing FT. Chi Square analysis was conducted between FT and non-FT patient groups. Additionally, survival analyses were performed to determine predictors of progression free and overall survival.
Results: 74 patients were included in this sample. 33/74 (44%) met criteria for FT. The average bad debt amount was $7,476.76 and the median debt amount was $2,015.96, with the average time to financial toxicity after surgery being approximately 127 days. FT patients were significantly younger at diagnosis than those who were not FT (64.6 years- non-FT vs. 59.0 years- FT, p = 0.0344). FT patients were more likely to have undergone subtotal resections rather than a gross total resection compared to non-FT patients (FT GTR 27.3%, non-FT GTR 52.4%, p = 0.028). Hospital length of stay was significantly longer for FT patients compared to non-FT patients (LOS FT 9.5 days, non-FT 6.5 days, p = 0.0312).
Conclusion: Glioblastoma patients are at high risk of experiencing FT with our series showing no significant impact on overall survival. Larger studies are needed to understand the impact of FT on patient outcomes.
Keywords: Financial toxicity; Glioblastoma; Neuro-oncology; Neurosurgical oncology; Oncology.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Fenn KM, Evans SB, McCorkle R et al (2014) Impact of Financial Burden of Cancer on survivors’ quality of life. JOP 10:332–338. https://doi.org/10.1200/JOP.2013.001322 - DOI - PubMed
-
- Longo CJ (2022) Linking Intermediate to final real-world outcomes: is Financial Toxicity a Reliable Predictor of Poorer outcomes in Cancer? Curr Oncol 29:2483–2489. https://doi.org/10.3390/curroncol29040202 - DOI - PubMed - PMC
-
- Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of Financial Toxicity among Cancer survivors: we can’t pay the co-pay. Patient 10:295–309. https://doi.org/10.1007/s40271-016-0204-x - DOI - PubMed
-
- Bouberhan S, Shea M, Kennedy A et al (2019) Financial toxicity in gynecologic oncology. Gynecol Oncol 154:8–12. https://doi.org/10.1016/j.ygyno.2019.04.003 - DOI - PubMed - PMC
-
- Hakki L, Khan A, Ehrich F et al (2023) Younger patients with Colon cancer are more likely to Experience Financial Toxicity Than older patients. Ann Surg Oncol 30:6837–6842. https://doi.org/10.1245/s10434-023-13911-8 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
